Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17991535 | 0.89 | ALOX15 (0.40) | NAMPTRAB9ANPC1CASP3SMN1; SMN2 | |
| SCHEMBL17957970 | 0.87 | HDAC6 (0.43) | RAB9ANPC1SMN1; SMN2TP53GLA | |
| SCHEMBL17957968 | 0.87 | HDAC6 (0.43) | RAB9ANPC1SMN1; SMN2TP53GLA | |
| SCHEMBL20909003 | 0.87 | HDAC6 (0.43) | RAB9ANPC1SMN1; SMN2TP53GLA | |
| SCHEMBL17957884 | 0.86 | AGTR1 (0.43) | NAMPTALOX15TSHRALDH1A1ATM | |
| SCHEMBL17957882 | 0.86 | AGTR1 (0.43) | NAMPTALOX15TSHRALDH1A1ATM | |
| SCHEMBL17991505 | 0.84 | NPC1 (0.41) | NAMPTRAB9ANPC1CASP3SMN1; SMN2 | |
| SCHEMBL17991532 | 0.83 | NPC1 (0.39) | RAB9ANPC1SMN1; SMN2ALOX15TSHR | |
| SCHEMBL17991530 | 0.82 | KDM4E (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL17991498 | 0.81 | NPC1 (0.39) | NAMPTRAB9ANPC1CASP3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2021-01-14 | — | — | US | disclosed |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2020-02-20 | — | — | US | disclosed |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2016126722-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-11279681-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | NAMPT 3951/4885RAB9A 3532/4885NPC1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.